Biohaven Pharmaceutical Holding Co Ltd (BHVN)

126.51
+3.59(+2.92%)
  • Volume:
    438,569
  • Bid/Ask:
    125.80/129.88
  • Day's Range:
    121.80 - 127.17

BHVN Overview

Prev. Close
122.92
Day's Range
121.8-127.17
Revenue
106.29M
Open
125.01
52 wk Range
58-128.12
EPS
-14.25
Volume
438,569
Market Cap
8.23B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
407,219
P/E Ratio
-
Beta
1.02
1-Year Change
81.64%
Shares Outstanding
65,073,919
Next Earnings Date
Nov 16, 2021
What is your sentiment on Biohaven Pharmaceutical Holding Co Ltd?
or
Market is currently closed. Voting is open during market hours.

Biohaven Pharmaceutical Holding Co Ltd News

Biohaven Pharmaceutical Holding Co Ltd Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

Biohaven Pharmaceutical Holding Co Ltd Company Profile

Biohaven Pharmaceutical Holding Co Ltd Company Profile

Sector
Services
Employees
825

Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The Company's glutamate platform includes three clinical-stage product candidates being developed for the treatment of various neurological indications: trigriluzole for the treatment of obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA) and Alzheimer's disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS), and BHV-5000 for the treatment of neurological and psychiatric illnesses such as Rett syndrome, neuropathic pain and treatment-resistant depression. BHV-0223 is developing for the treatment of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord. The Company also develops bispecific compounds that is designed to emulate or enhance the activity of biologics.

Read More
  • overbought but good as long term investment
    0
    • Market Cap 5.45B, Revenue 28.51M...DUUUMP!!!
      0
      • khloe Kardashian promoting on ABC the View.
        0
        • $BHVN Buy this before the Phase 3 data announcement TRORILUZOLE and Rimegepant this month! I am assuming 2/20 or so..This stock can go to $80's.
          0
          • What is the special event on 20th Feb?
            0
        • stock tanked 35% today
          0
          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.